title: Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
abstract: Cytokine-induced killer (CIK) cells consist of a heterogeneous population of polyclonal T lymphocytes displaying NK phenotype and HLA-unrestricted cytotoxic activity against a broad range of tumors. We sought to determine whether transduction of CIK cells with T cell receptor (TCR) genes specific for tumor-associated antigens could generate effector cells endowed with a double mechanism of tumor recognition. HLA-A2-restricted TCR-transduced (TD) CIK directed against the melanoma antigens Mart1 and NY-ESO1 were generated by lentiviral transduction and successfully expanded over a 3-4-week period. TD-CIK cells were both CD3(+)/CD56(-) and CD3(+)/CD56(+) (31±8% and 59±9%, respectively), indicating that both major histocompatibility complex (MHC)-restricted T cells and MHC-unrestricted CIK could be targeted by lentiviral transduction. At the end of the culture, the majority of both unmodified and TD-CIK displayed an effector memory phenotype, without considerable expression of replicative senescence and exhaustion markers. Functionally, TD-CIK specifically recognized tumor cells expressing the relevant antigen as well as maintained their MHC-unrestricted tumor activity. The cytotoxic activity of TD-CIK against HLA-A2(+) melanoma cell lines was significantly higher than the untransduced counterparts at a low effector:target ratio (cytotoxic activity of TD-CIK was from 1.9- to 4.3-fold higher than untransduced counterparts). TD-CIK were highly proficient in releasing high amount of IFN-γ upon antigen-specific stimulation and were able to recognize primary melanoma targets. In conclusion, we showed that (1) the reproducibility and simplicity of CIK transduction and expansion might solve the problem of obtaining adequate numbers of potent antitumor effector cells for adoptive immunotherapy; (2) the presence of both terminal effectors as well as of less differentiated progenitors might confer them long survival in vivo; and (3) the addition of an MHC-restricted antigen recognition allows not only targeting tumor surface antigens but also a wider range of cytoplasmic or nuclear antigens, involved in tumor proliferation and survival. TD-CIK cells with a double mechanism of tumor recognition are an attractive and alternative tool for the development of efficient cell therapeutic strategies.
authors.affiliation: 1 Molecular Biotechnology Center, University of Torino , 10126 Turin, Italy .
authors.forename: Angela R
authors.initials: AR
authors.lastname: Elia
authors.forename: Paola
authors.initials: P
authors.lastname: Circosta
authors.forename: Dario
authors.initials: D
authors.lastname: Sangiolo
authors.forename: Chiara
authors.initials: C
authors.lastname: Bonini
authors.forename: Loretta
authors.initials: L
authors.lastname: Gammaitoni
authors.forename: Sara
authors.initials: S
authors.lastname: Mastaglio
authors.forename: Pietro
authors.initials: P
authors.lastname: Genovese
authors.forename: Massimo
authors.initials: M
authors.lastname: Geuna
authors.forename: Fabio
authors.initials: F
authors.lastname: Avolio
authors.forename: Giorgio
authors.initials: G
authors.lastname: Inghirami
authors.forename: Corrado
authors.initials: C
authors.lastname: Tarella
authors.forename: Alessandro
authors.initials: A
authors.lastname: Cignetti
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D045744:Cell Line, Tumor; D016207:Cytokines / Q000502:physiology*; D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D055611:Natural Killer T-Cells / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000951:Antigens, Neoplasm; D016207:Cytokines; D011948:Receptors, Antigen, T-Cell